Latest Ratios: P/E Ratio -2.5x · EV/EBITDA N/A · ROE -110.7%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $147M | $75M | $340M | $73M | $49M | $1.1B | $1.1B | $541M | — | — |
| Enterprise Value | $168M | $97M | $329M | $-59642644 | $179M | $1.1B | $963M | $341M | — | — |
| P/E Ratio → | -2.48 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 113.63 | 11.77 | 149.54 | — | — | — | 30.75 | 18.68 | — | — |
| P/B Ratio | 2.69 | 1.46 | 2.12 | 0.43 | — | 8.72 | 5.91 | 3.23 | — | — |
| P/FCF | — | — | — | — | — | — | — | 16.31 | — | — |
| P/OCF | — | — | — | — | — | — | — | 15.80 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.16 | 144.75 | — | — | — | 26.04 | 11.76 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 10.27 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.0% | 33.0% | 100.0% | — | — | — | 95.7% | 41.9% | — | — |
| Operating Margin | -1366.4% | -1366.4% | -4047.1% | — | — | — | -74.5% | -71.4% | — | — |
| Net Profit Margin | -1834.5% | -1834.5% | -3680.4% | — | — | — | -71.7% | -64.8% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.7% | -110.7% | -50.6% | -229.0% | -365.1% | -13.6% | -14.7% | -30.5% | — | — |
| ROA | -69.0% | -69.0% | -37.3% | -55.0% | -44.8% | -9.8% | -10.9% | -14.0% | -59.6% | -102.3% |
| ROIC | -58.8% | -58.8% | -73.9% | -186.5% | -69.2% | -46.3% | -113.9% | — | — | — |
| ROCE | -55.8% | -55.8% | -44.5% | -63.3% | -49.4% | -17.2% | -13.5% | -19.6% | -64.9% | -92.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | 0.28 | 0.20 | — | 0.35 | 0.24 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.42 | -0.07 | -0.78 | — | -0.26 | -0.91 | -1.20 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -6.04 | — | — |
| Interest Coverage | — | — | — | — | -499.98 | — | — | — | -179.83 | -115.30 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.90 | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 | 8.45 | 4.19 | 11.38 | 8.07 |
| Quick Ratio | 6.90 | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 | 8.45 | 4.19 | 11.38 | 8.07 |
| Cash Ratio | 6.30 | 6.30 | 8.43 | 8.53 | 6.42 | 11.44 | 8.27 | 4.12 | 11.18 | 8.06 |
| Asset Turnover | — | 0.06 | 0.01 | — | — | — | 0.14 | 0.13 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 55.33 | 272.58 | — | — | — | 3.36 | 10.15 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 6.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $9M | $9M | $2M | $255174 | $4M | $645064 | $616890 | $627085 | $627085 |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRRO stock.
Korro Bio, Inc.'s current P/E ratio is -2.5x. This places it at the 50th percentile of its historical range.
Korro Bio, Inc.'s return on equity (ROE) is -110.7%. The historical average is -116.3%.
Based on historical data, Korro Bio, Inc. is trading at a P/E of -2.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Korro Bio, Inc. has 33.0% gross margin and -1366.4% operating margin.
Key Metrics
Top Statement Risk
Cash runway shrinking against burn
Metrics are mathematically derived from official filings.
Price-to-Book Premium Reflects Pipeline Optionality
Based on Korro Bio's reported figures, the stock trades at 2.69 times book value and 22.97 times sales while reporting negative earnings, so the market appears to be pricing pipeline optionality rather than current earnings power, and the P/E of -1.18 is not meaningful as an anchor.
With no positive earnings, the P/E and EV/EBITDA multiples cannot be interpreted and should be excluded from valuation work. The 22.97 price-to-sales ratio, on a revenue base that has largely disappeared, implies the market is capitalizing clinical milestones rather than commercial output. Investors should monitor whether the 2.69 price-to-book premium holds as tangible equity erodes toward roughly $103M.
Low Debt Ratio Masks Thin Cash Cover
As reported in financial statements, Korro Bio's debt-to-equity ratio of 0.41 at 2026Q2 looks modest, but interest coverage and EBITDA-based leverage are not computable because operating earnings are negative, so leverage metrics likely understate near-term financial pressure.
The debt-to-equity figure has risen from 0.19 in 2024Q2 to 0.41 in 2026Q2, which suggests leverage is increasing as equity shrinks rather than as debt is added deliberately. With interest coverage unavailable, the company's ability to service its $42.2M debt load cannot be assessed from earnings, leaving cash on hand as the only visible support. Warrants further investigation into debt maturity and covenant terms, which are not disclosed in the supplied data.
Current Ratio Overstates Practical Liquidity
Based on reported figures, the current ratio of 9.55 at 2026Q2 appears strong, yet cash of $24.9M covers less than one quarter of the $33.1M free cash outflow, so headline liquidity may be misleading, and the ratio has fallen from 13.28 in 2024Q2.
A high current ratio coexisting with a shrinking cash balance suggests current assets are dominated by items other than readily deployable cash, which warrants further investigation. The decline from 13.28 to 9.55 over eight quarters indicates liquidity is eroding even as the ratio remains elevated. Under continued burn at the most recent pace, the cash position would likely require new financing or partnership proceeds within the near term.
Persistent Negative Returns Erode Equity Base
According to recent SEC filings, Korro Bio's ROE of -17.0% and ROIC of -13.6% at 2026Q2 remain negative across all ten quarters, indicating capital is being consumed rather than compounded, while ROA has hovered near -11% throughout the period.
Negative ROIC in every reported quarter means the company has not earned a return on the capital deployed, a pattern typical of pre-commercial biotechnology but still value-destructive on a reported basis. The ROE swings, including -66.5% in 2025Q4, appear driven by large non-operating charges rather than a stable operating trend. Investors should monitor whether returns trend toward zero as pipeline spend moderates or deepen as the equity base contracts.
Balance Sheet Lighter Than Most Peers
Based on Korro Bio's reported figures, its debt-to-equity of 0.41 sits above Beam's 0.24, CRISPR's 0.21, and Intellia's 0.14, but below Prime Medicine's 0.96 and Editas's 2.81, placing it mid-pack on leverage among gene-editing peers.
Korro's ROE of -17.0% is materially less negative than Editas, Prime, and CRISPR, which suggests its losses are smaller relative to equity than several peers. Its net margin is not comparable because most peers also lack meaningful revenue, which limits the usefulness of margin comparisons. The leverage position appears structurally mid-range, while the return gap versus peers may be partly temporary, reflecting the timing of non-operating charges.
Price-to-Sales Misleads on Pre-Revenue Biotech
Per reported figures, the 22.97 price-to-sales ratio is the metric most commonly misapplied to this business, since Korro's revenue base has shrunk toward zero, so the multiple obscures how little commercial value the sales line currently supports.
Price-to-sales is often applied to biotech as if revenue were a proxy for scale, but here the denominator is a collapsing, lumpy collaboration income stream rather than product sales. A better frame is price relative to cash and pipeline burn, such as enterprise value per dollar of cash runway, which directly reflects the shrinking $24.9M cash position against $33.1M quarterly outflow. Investors should weight this runway-based measure above any sales multiple when assessing the equity.